Maxdulin 75/20 Capsule DR is a combination pharmaceutical formulation containing Pregabalin 75 mg and Duloxetine 20 mg, designed for the management of neuropathic pain and associated depressive symptoms. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channel function, thereby reducing neurotransmitter release and alleviating neuropathic pain. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), enhances central pain modulation and improves mood by increasing the levels of serotonin and norepinephrine in the central nervous system. The delayed-release (DR) capsule formulation ensures optimal absorption and sustained therapeutic effect. Maxdulin 75/20 is indicated for patients suffering from diabetic peripheral neuropathy, fibromyalgia, and generalized anxiety disorder with comorbid neuropathic pain. It may also be prescribed for major depressive disorder where neuropathic pain is a contributing factor. The combination therapy offers synergistic benefits, addressing both pain and mood symptoms effectively. Patients should use this medication under strict medical supervision due to potential side effects such as dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment. Maxdulin 75/20 Capsule DR should be taken as prescribed, with dosage adjustments based on clinical response and tolerability.